Overview


According to FutureWise analysis the market for circulating tumor cells (CTCs) and cancer stem cells (CSCs) in 2023 is US$ 16.34 billion, and is expected to reach US$ 47.66 billion by 2031 at a CAGR of 14.3%.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • ApoCell
  • IVDiagnostics
  • YZY Bio
  • Janssen
  • Fluxion
  • BioView
  • Cynvenio
  • Aviva Biosciences Corporation
  • Gilupi
  • On-chip
  • Advanced Cell Diagnostics
  • Creatv MicroTech
  • Qiagen
  • Biofluidica
  • Celsee
  • Ikonisys
  • CytoTrack
  • AdnaGen
  • ScreenCell
  • Silicon Biosystems
  • Clearbridge Biomedics
  • Miltenyi Biotec
  • Fluidigm

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Types

  • CellSearch
  • Oncoquick
  • ISET
  • MACS
  • Others

By Application

  • Breast Cancer Diagnosis and Treatment
  • Prostate Cancer Diagnosis and Treatment
  • Colorectal Cancer Diagnosis and Treatment
  • Lung Cancer Diagnosis and Treatment
  • Other Cancers Diagnosis and Treatment

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market By Types, By Application and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market, By Types Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. CellSearch
        2. Oncoquick
        3. ISET
        4. MACS
        5. Others

  • 8.   Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Breast Cancer Diagnosis and Treatment
        2. Prostate Cancer Diagnosis and Treatment
        3. Colorectal Cancer Diagnosis and Treatment
        4. Lung Cancer Diagnosis and Treatment
        5. Other Cancers Diagnosis and Treatment

  • 9.   North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. ApoCell
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. IVDiagnostics
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. YZY Bio
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Janssen
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Fluxion
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. BioView
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Cynvenio
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Aviva Biosciences Corporation
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Gilupi
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
         10. On-chip
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
          11. Advanced Cell Diagnostics
         11.1. Company Overview
         11.2. Targeted Antigen Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
          12. Creatv MicroTech
         12.1. Company Overview
         12.2. Targeted Antigen Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
          13. Qiagen
         13.1. Company Overview
         13.2. Targeted Antigen Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
          14. Biofluidica
         14.1. Company Overview
         14.2. Targeted Antigen Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
          15. Celsee
         1. Company Overview
         2. Targeted Antigen Portfolio
         3. SWOT Analysis
         4. Financial Overview
         5. Strategic Overview
          16. Ikonisys
         16.1. Company Overview
         16.2. Targeted Antigen Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
          17. CytoTrack
         17.1. Company Overview
         17.2. Targeted Antigen Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
           18. AdnaGen
         18.1. Company Overview
         18.2. Targeted Antigen Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
          19. ScreenCell
         19.1. Company Overview
         19.2. Targeted Antigen Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview
         20. Silicon Biosystems
         20.1. Company Overview
         20.2. Targeted Antigen Portfolio
         20.3. SWOT Analysis
         20.4. Financial Overview
         20.5. Strategic Overview
         21. Clearbridge Biomedics
         21.1. Company Overview
         21.2. Targeted Antigen Portfolio
         21.3. SWOT Analysis
         21.4. Financial Overview
         21.5. Strategic Overview
          22. Miltenyi Biotec
         22.1. Company Overview
         22.2. Targeted Antigen Portfolio
         22.3. SWOT Analysis
         22.4. Financial Overview
         22.5. Strategic Overview
         23. Fluidigm
         23.1. Company Overview
         23.2. Targeted Antigen Portfolio
         23.3. SWOT Analysis
         23.4. Financial Overview
         23.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients